Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Assembly Biosciences and Gilead announce partnership for GS-1179 focusing on flexible financial benefits.

Aug 16, 2026•about 5 hours ago

Contract Type

partnership

San FranciscoBiotechnologyHealth CareTherapeutics

Description

Assembly Biosciences has partnered with Gilead on GS-1179, targeting genital herpes and benefiting from flexible financial arrangements. The company maintains a strong cash reserve of $320.4 million and is positioned for clinical development through 2029. Key trial results are expected between 2027 and 2028, driving growth and stability.

Company Information

Company

Assembly Biosciences

Location

San Francisco, California, United States

About

Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Assembly Biosciences's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.